Occurrence of serum anti-HLA Abs detected by CDC 30 days after BMT or PBHSCT
| Ab isotype . | Presence of anti-HLA Ab . | P . | |||
|---|---|---|---|---|---|
| Donors . | Recipients pretransplantation . | Recipients at day + 30 . | |||
| PBHSCT (%) . | BMT (%) . | ||||
| Anti-HLA IgG Ab | All | All | 5/24 (21) | 1/27 (4) | .09 |
| Negative | Negative | 4/23 (17) | 0/26 | .04 | |
| Positive | Negative | 1/1 | — | — | |
| Negative | Positive | — | 1/1 | — | |
| Anti-HLA IgM Ab | All | All | 8/24 (33) | 0/27 | .001 |
| Negative | Negative | 8/24 (33) | 0/26 | .001 | |
| Positive | Negative | 0 | 0/1 | — | |
| Negative | Positive | 0 | 0 | — | |
| Ab isotype . | Presence of anti-HLA Ab . | P . | |||
|---|---|---|---|---|---|
| Donors . | Recipients pretransplantation . | Recipients at day + 30 . | |||
| PBHSCT (%) . | BMT (%) . | ||||
| Anti-HLA IgG Ab | All | All | 5/24 (21) | 1/27 (4) | .09 |
| Negative | Negative | 4/23 (17) | 0/26 | .04 | |
| Positive | Negative | 1/1 | — | — | |
| Negative | Positive | — | 1/1 | — | |
| Anti-HLA IgM Ab | All | All | 8/24 (33) | 0/27 | .001 |
| Negative | Negative | 8/24 (33) | 0/26 | .001 | |
| Positive | Negative | 0 | 0/1 | — | |
| Negative | Positive | 0 | 0 | — | |